HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New: Introducing “Why Is It Moving?” - lightning-fast, AI-driven explanations of stock moves

Learn More
Open in Screener

COGT

Cogent Biosciences Inc

Last Close
Oct 07  •  03:17PM ET
15.50
Dollar change
-0.40
Percentage change
-2.52 %
Healthcare • Biotechnology • USA • NASD
Peers: BLUE VRTX BEAM CRSP BPMC NTLA GILD EDIT ALLO FATE
 | Held by: IWM VTI XBI IWO VXF SCHA IBB VTWO IWC LFSC
IndexRUT P/E- EPS (ttm)-2.42 Insider Own19.43% Shs Outstand113.93M Perf Week7.94%
Market Cap2.17B Forward P/E- EPS next Y-1.84 Insider Trans11.40% Shs Float112.56M Perf Month22.24%
Enterprise Value2.10B PEG- EPS next Q-0.52 Inst Own87.38% Short Float13.36% Perf Quarter49.04%
Income-271.56M P/S- EPS this Y11.38% Inst Trans6.46% Short Ratio5.61 Perf Half Y238.43%
Sales0.00M P/B37.48 EPS next Y15.58% ROA-80.62% Short Interest15.04M Perf YTD98.72%
Book/sh0.41 P/C9.10 EPS next 5Y30.50% ROE-107.55% 52W High16.22 -4.41% Perf Year46.92%
Cash/sh1.70 P/FCF- EPS past 3/5Y-9.70% 10.02% ROIC-126.88% 52W Low3.72 316.67% Perf 3Y3.89%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility5.37% 4.70% Perf 5Y65.60%
Dividend TTM- EV/Sales- EPS Y/Y TTM2.25% Oper. Margin- ATR (14)0.66 Perf 10Y-
Dividend Ex-Date- Quick Ratio4.19 Sales Y/Y TTM- Profit Margin- RSI (14)71.16 Recom1.50
Dividend Gr. 3/5Y- - Current Ratio4.19 EPS Q/Q-8.15% SMA2014.43% Beta0.40 Target Price21.09
Payout- Debt/Eq0.39 Sales Q/Q- SMA5023.39% Rel Volume0.43 Prev Close15.90
Employees205 LT Debt/Eq0.38 EarningsAug 05 BMO SMA20080.40% Avg Volume2.68M Price15.50
IPOMar 29, 2018 Option/ShortYes / Yes EPS/Sales Surpr.-0.07% - Trades Volume1,021,101 Change-2.52%
Date Action Analyst Rating Change Price Target Change
Sep-03-25Initiated Raymond James Strong Buy $30
Mar-07-25Initiated Scotiabank Sector Outperform $17
Dec-11-24Downgrade Needham Buy → Hold
Feb-26-24Downgrade Robert W. Baird Outperform → Neutral $14 → $8
Feb-08-24Initiated Citigroup Buy $11
Dec-11-23Downgrade Wedbush Outperform → Neutral $5
Dec-08-23Initiated JP Morgan Overweight $18
Apr-28-23Initiated Robert W. Baird Outperform $20
Mar-27-23Resumed H.C. Wainwright Buy $28
Dec-14-22Initiated Needham Buy $24
Show Previous Ratings
Sep-29-25 04:05PM
Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Sep-16-25 12:59PM
Cogent, Dime added to Raymond James analyst favorites list
(Investing.com)
Aug-26-25 08:00AM
Cogent Biosciences Announces Participation in the Citi Biopharma Conference
(GlobeNewswire)
Aug-05-25 08:00AM
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2025 Financial Results
(GlobeNewswire) -5.73%
Jul-31-25 05:31PM
KIT Inhibitors Market Growth: Key Trends and Future Projections in the 7MM Upto 2034 | DelveInsight
(PR Newswire)
11:47PM Loading…
Jul-24-25 11:47PM
Cogent Biosciences Rated as a Buy at Citi on Robust Pipeline
(Insider Monkey)
Jul-18-25 06:19PM
Rocket, TaskUS, Appian, and More Stocks See Action From Activist Investors
(Barrons.com)
Jul-16-25 12:23PM
Jefferies Raises Cogent Biosciences (COGT) PT, Keeps Buy Rating
(Insider Monkey)
Jul-10-25 04:01PM
Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
(GlobeNewswire)
Jul-08-25 09:36PM
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock
(GlobeNewswire) +6.34%
04:26PM
Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock
(GlobeNewswire)
10:54AM
COGT Stock Soars on Phase III Systemic Mastocytosis Study Success
(Zacks)
Jul-07-25 07:06AM
Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis
(GlobeNewswire) +23.35%
Jun-11-25 08:00AM
Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing
(GlobeNewswire)
May-29-25 08:00AM
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference
(GlobeNewswire) +12.91%
09:55AM Loading…
May-13-25 09:55AM
Wall Street Analysts Believe Cogent Biosciences (COGT) Could Rally 224.37%: Here's is How to Trade
(Zacks)
08:50AM
Why Cogent Biosciences (COGT) Is One of the Best Low Priced Biotech Stocks to Buy Now
(Insider Monkey)
May-06-25 08:00AM
Cogent Biosciences Reports First Quarter 2025 Financial Results
(GlobeNewswire) -15.62%
May-05-25 07:57AM
Is Cogent Biosciences, Inc. (COGT) the Best Small Cap Stock to Buy with the Biggest Upside Potential?
(Insider Monkey) -5.11%
Apr-25-25 08:08AM
Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders
(GlobeNewswire)
Apr-20-25 06:16AM
Cogent Biosciences (COGT): Among the Most Promising Penny Stocks According to Analysts
(Insider Monkey)
Apr-16-25 10:03AM
Is Cogent Biosciences Inc. (NASDAQ:COGT) the Best Biotech Penny Stock to Buy According to Hedge Funds?
(Insider Monkey) -12.32%
Apr-09-25 04:28PM
Cogent: Several 2025 Readouts On Deck With Bezuclastinib Advancement
(Seeking Alpha) +7.73% -9.87%
Mar-25-25 04:31PM
Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
(GlobeNewswire) -6.76% -6.23%
Mar-20-25 08:32AM
Is Cogent Biosciences (COGT) Stock a Solid Choice Right Now?
(Zacks)
Mar-07-25 08:00AM
Cogent Biosciences Announces Participation in the Leerink Healthcare Conference
(GlobeNewswire) -5.40%
Feb-27-25 08:00AM
Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
(GlobeNewswire)
Feb-25-25 08:00AM
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
(GlobeNewswire) -6.30%
Feb-10-25 09:15AM
Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting
(GlobeNewswire)
Jan-30-25 08:00AM
Cogent Biosciences to Participate in the Guggenheim Biotech Conference
(GlobeNewswire)
08:00AM Loading…
Jan-13-25 08:00AM
Cogent Biosciences Announces Planned 2025 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
(GlobeNewswire)
Jan-08-25 08:00AM
Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
(GlobeNewswire)
Dec-09-24 07:00AM
Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
(GlobeNewswire) +8.77%
Dec-08-24 12:00PM
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
(GlobeNewswire)
Nov-05-24 09:00AM
Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting
(GlobeNewswire) -15.84%
Oct-23-24 07:00AM
Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics
(GlobeNewswire)
Oct-09-24 08:03AM
Analysts Rate Cogent Biosciences, Inc. (COGT) as Moderate Buy with $15 Target
(Insider Monkey)
Sep-03-24 08:00AM
Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis
(GlobeNewswire)
Sep-02-24 05:22PM
10 Best Small-Cap Healthcare Stocks To Buy Now
(Insider Monkey)
Aug-06-24 08:00AM
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results
(GlobeNewswire)
Jun-28-24 09:18AM
Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting
(Zacks)
Jun-27-24 08:00AM
Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT Trial
(GlobeNewswire)
Jun-14-24 07:30AM
Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
(GlobeNewswire) -6.18%
May-23-24 05:05PM
Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer
(GlobeNewswire) -6.72% +9.75%
05:01PM
Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting
(GlobeNewswire)
May-07-24 01:52PM
COGT Stock Earnings: Cogent Biosciences Misses EPS for Q1 2024
(InvestorPlace)
08:00AM
Cogent Biosciences Reports First Quarter 2024 Financial Results
(GlobeNewswire)
Apr-09-24 09:00AM
Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor
(GlobeNewswire) +7.21%
Mar-13-24 07:06AM
5 Best Biotech Stocks To Buy Under $20
(Insider Monkey)
Feb-28-24 04:32AM
COGT Reports Full Year 2023 Financial Results and Business Highlights
(GuruFocus.com)
Feb-26-24 08:00AM
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
(GlobeNewswire)
Feb-22-24 02:30PM
Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis
(GlobeNewswire)
Feb-14-24 07:00AM
Cogent Biosciences Announces Oversubscribed $225 Million Private Placement
(GlobeNewswire) +59.34%
Feb-05-24 09:00AM
Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting
(GlobeNewswire) +18.75%
Jan-09-24 08:00AM
Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics
(GlobeNewswire) -7.73%
Jan-02-24 08:00AM
Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
(GlobeNewswire) +6.12%
Dec-11-23 07:55AM
Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
(GlobeNewswire) -53.01%
Dec-09-23 01:30PM
Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM)
(GlobeNewswire)
Dec-07-23 09:00AM
Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3K inhibitor programs at the San Antonio Breast Cancer Symposium
(GlobeNewswire)
Dec-04-23 08:00AM
Cogent Biosciences to Host Investor Webcast on December 11, 2023 at 8:00 AM ET to Review Clinical Data Being Presented at American Society of Hematology (ASH) Annual Meeting
(GlobeNewswire)
Nov-29-23 08:00AM
Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium
(GlobeNewswire) +5.67%
Nov-02-23 09:00AM
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results
(GlobeNewswire)
Oct-14-23 12:30PM
Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
(GlobeNewswire)
Aug-13-23 08:51AM
After losing 15% in the past year, Cogent Biosciences, Inc. (NASDAQ:COGT) institutional owners must be relieved by the recent gain
(Simply Wall St.)
Aug-08-23 08:00AM
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results
(GlobeNewswire) +7.62%
Jul-10-23 07:35PM
Analysts Say These 2 Stocks Are Their Top Picks for the Rest of 2023
(TipRanks)
Jun-09-23 04:01PM
Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock
(GlobeNewswire)
Jun-07-23 09:00AM
Cogent Biosciences Announces Participation in the Jefferies Healthcare Conference
(GlobeNewswire) -10.21%
Jun-06-23 08:25PM
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock
(GlobeNewswire)
04:05PM
Cogent Biosciences Announces Proposed Public Offering of Common Stock
(GlobeNewswire)
Jun-03-23 02:15PM
Cogent Biosciences Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST)
(GlobeNewswire)
May-23-23 08:00AM
Cogent Biosciences to Host Investor Webcast to Discuss Lead-In Data Being Presented at ASCO from the Ongoing Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST)
(GlobeNewswire)
May-09-23 08:00AM
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2023 Financial Results
(GlobeNewswire)
Apr-17-23 09:00AM
Cogent Biosciences Presents Preclinical Data at AACR Annual Meeting Highlighting Precision Therapy Pipeline and Announces Initiation of Part 2 of the Registration-Enabling APEX Trial with Bezuclastinib in Advanced Systemic Mastocytosis
(GlobeNewswire) +6.62%
Apr-12-23 08:00AM
Cogent Biosciences Announces Participation at Upcoming Investor Conferences
(GlobeNewswire) -5.74%
Mar-14-23 08:00AM
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
(GlobeNewswire) +7.54%
Feb-01-23 08:00AM
Cogent Biosciences Announces Participation at Upcoming Investor Conferences
(GlobeNewswire)
Jan-11-23 11:03AM
Companies Like Cogent Biosciences (NASDAQ:COGT) Are In A Position To Invest In Growth
(Simply Wall St.)
Jan-09-23 08:00AM
Cogent Biosciences Announces Planned 2023 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Cancer Therapeutics
(GlobeNewswire)
Jan-05-23 08:00AM
Cogent Biosciences Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
(GlobeNewswire)
Dec-11-22 05:30PM
Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
(GlobeNewswire)
Dec-05-22 08:00AM
Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis
(GlobeNewswire)
Nov-28-22 04:15PM
Cogent Biosciences Appoints Rachael Easton, MD, Ph.D., VP, Head of Clinical Development
(GlobeNewswire) +6.14%
Nov-14-22 07:00AM
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results
(GlobeNewswire)
Nov-09-22 08:00AM
Cogent Biosciences Announces Participation at Upcoming Investor Conferences
(GlobeNewswire) -5.63%
Nov-03-22 09:05AM
Cogent Biosciences Announces Bezuclastinib Presentations at the 64th Annual American Society of Hematology (ASH) Meeting
(GlobeNewswire)
Oct-26-22 07:00AM
Cogent Biosciences to Showcase Precision Therapy Pipeline at the EORTC-NCI-AACR Annual Meeting
(GlobeNewswire)
Aug-14-22 12:21PM
2 Monster Growth Stocks That Could Reach New Highs
(TipRanks)
Aug-09-22 07:00AM
Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2022 Financial Results
(GlobeNewswire)
Aug-04-22 11:22AM
Companies Like Cogent Biosciences (NASDAQ:COGT) Are In A Position To Invest In Growth
(Simply Wall St.) +12.58%
Jun-20-22 11:09AM
Is Cogent Biosciences, Inc. (NASDAQ:COGT) Popular Amongst Institutions?
(Simply Wall St.)
Jun-16-22 04:01PM
Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters Option to Purchase Additional Shares
(GlobeNewswire) -6.47% +17.82%
Jun-13-22 09:48PM
Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock and Pre-funded Warrants
(GlobeNewswire) +11.05%
06:00AM
Cogent Biosciences Announces Proposed Public Offering of Common Stock
(GlobeNewswire)
Jun-10-22 07:00AM
Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
(GlobeNewswire) +58.67%
Jun-06-22 10:15AM
Cogent Biosciences to Host Investor Webcast on June 10, 2022 at 8:00am ET
(GlobeNewswire)
Jun-02-22 08:00AM
Cogent Biosciences Announces Annual Meeting of Stockholders
(GlobeNewswire)
May-12-22 10:00AM
Cogent Biosciences Announces Presentation at European Hematology Association (EHA) Annual Congress
(GlobeNewswire) -7.11%
May-10-22 07:00AM
Cogent Biosciences Reports Recent Business Highlights and First Quarter 2022 Financial Results
(GlobeNewswire) -8.29%
May-06-22 08:00AM
Cogent Biosciences to Participate in the LifeSci Partners Immunology and Inflammation Symposium
(GlobeNewswire)
Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fairmount Funds Management LLCDirectorJul 10 '25Buy9.002,777,77724,999,9939,003,418Jul 14 04:30 PM
Pinnow ColeChief Commercial OfficerJan 14 '25Buy7.6043,750332,41245,848Jan 15 07:00 AM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

VRDN

Viridian Therapeutics Inc

Last Close
Oct 07  •  03:17PM ET
20.90
Dollar change
+0.07
Percentage change
0.34 %
Healthcare • Biotechnology • USA • NASD
VRDN Viridian Therapeutics Inc daily Stock Chart
Peers: REGN VRTX EXEL SRPT BMRN ALNY RARE IONS ADAP PBYI
 | Held by: VTI IWM XBI VXF IWO SCHA VTWO IWC VHT IWN
IndexRUT P/E- EPS (ttm)-4.27 Insider Own9.93% Shs Outstand81.65M Perf Week-3.15%
Market Cap1.71B Forward P/E- EPS next Y-4.04 Insider Trans0.00% Shs Float73.55M Perf Month5.50%
Enterprise Value1.36B PEG- EPS next Q-0.95 Inst Own106.23% Short Float14.96% Perf Quarter22.65%
Income-328.98M P/S5689.15 EPS this Y-9.88% Inst Trans2.10% Short Ratio14.43 Perf Half Y77.42%
Sales0.30M P/B5.23 EPS next Y2.50% ROA-56.33% Short Interest11.00M Perf YTD9.02%
Book/sh4.00 P/C3.03 EPS next 5Y19.51% ROE-62.99% 52W High27.20 -23.16% Perf Year-12.48%
Cash/sh6.90 P/FCF- EPS past 3/5Y22.74% 31.28% ROIC-62.16% 52W Low9.90 111.11% Perf 3Y1.90%
Dividend Est.- EV/EBITDA- Sales past 3/5Y-53.29% -41.64% Gross Margin-255.08% Volatility4.25% 4.79% Perf 5Y79.78%
Dividend TTM- EV/Sales4517.69 EPS Y/Y TTM-0.36% Oper. Margin-121831.15% ATR (14)0.92 Perf 10Y-90.40%
Dividend Ex-Date- Quick Ratio11.01 Sales Y/Y TTM5.90% Profit Margin-107863.61% RSI (14)58.83 Recom1.12
Dividend Gr. 3/5Y- - Current Ratio11.01 EPS Q/Q-21.30% SMA204.60% Beta0.78 Target Price39.13
Payout- Debt/Eq0.04 Sales Q/Q4.17% SMA5010.68% Rel Volume0.40 Prev Close20.83
Employees143 LT Debt/Eq0.03 EarningsAug 06 BMO SMA20026.77% Avg Volume762.40K Price20.90
IPOJun 18, 2014 Option/ShortYes / Yes EPS/Sales Surpr.0.91% 47.35% Trades Volume270,778 Change0.34%
Date Action Analyst Rating Change Price Target Change
Aug-25-25Resumed Jefferies Buy $44
Dec-19-24Downgrade Wells Fargo Overweight → Equal Weight $37 → $27
Nov-25-24Initiated TD Cowen Buy
Sep-11-24Reiterated Needham Buy $30 → $38
Jun-11-24Initiated Wolfe Research Outperform $29
Jun-06-24Initiated Goldman Buy $23
May-09-24Downgrade Ladenburg Thalmann Buy → Neutral
May-09-24Downgrade B. Riley Securities Buy → Neutral $25 → $20
Jun-14-23Resumed Credit Suisse Outperform $51
Jun-14-23Initiated BTIG Research Buy $46
Show Previous Ratings
Oct-02-25 04:00PM
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Sep-15-25 07:01AM
Viridian Therapeutics Announces Completion of Enrollment in both REVEAL Clinical Trials and Positive Portfolio Updates
(Business Wire)
Sep-03-25 04:01PM
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Aug-17-25 11:41PM
Viridian Therapeutics, Kissei Pharmaceutical Partner for Japanese Development of Thyroid Eye Disease Therapies, Securing $70M Upfront
(Insider Monkey)
Aug-06-25 07:45AM
Viridian Therapeutics, Inc. (VRDN) Reports Q2 Loss, Misses Revenue Estimates
(Zacks)
06:30AM Loading…
06:30AM
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2025 Financial Results
(Business Wire)
Aug-04-25 07:00AM
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Jul-31-25 05:37AM
Viridian and Kissei to advance veligrotug and VRDN-003 in Japan
(Pharmaceutical Technology)
Jul-30-25 08:30AM
Madrigal buys into GLP-1 from CSPC; Apellis wins expanded drug approval
(BioPharma Dive) +6.02%
04:00AM
Viridian Therapeutics Announces Collaboration and License Agreement with Kissei Pharmaceutical to Develop and Commercialize Veligrotug and VRDN-003 in Japan with an Upfront Payment of $70 Million and up to $315 Million in Milestone Payments
(Business Wire)
Jul-15-25 08:58AM
Viridian Therapeutics' Veligrotug Shows Durable Proptosis Response in Phase 3 TED Trial
(Insider Monkey) -5.13%
Jul-03-25 07:00AM
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Jun-05-25 07:00AM
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
May-30-25 07:00AM
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
(Business Wire)
May-20-25 07:00AM
Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)
(Business Wire) +7.80%
04:15PM Loading…
May-07-25 04:15PM
Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)
(Business Wire)
May-06-25 08:10AM
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates
(Zacks) -8.31%
07:00AM
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results
(Business Wire)
May-02-25 07:00AM
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Apr-15-25 08:09AM
Argenx (ARGX) Moves 4.4% Higher: Will This Strength Last?
(Zacks)
Apr-07-25 07:00AM
Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors
(Business Wire)
Mar-19-25 05:07PM
Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward
(SeekingAlpha)
Mar-10-25 07:00AM
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Feb-27-25 07:00AM
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results
(Business Wire)
Feb-06-25 04:01PM
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Jan-08-25 07:00AM
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease
(Business Wire) -8.42%
Dec-17-24 07:40AM
Viridian Therapeutics announces THRIVE-2 trial met primary, secondary endpoints
(TipRanks)
Dec-16-24 04:09PM
Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen
(Investor's Business Daily) +20.67%
09:28AM
Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease
(Investor's Business Daily)
07:00AM
Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease
(Business Wire)
06:00PM Loading…
Dec-13-24 06:00PM
Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024
(Business Wire)
Dec-04-24 04:01PM
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Nov-12-24 07:00AM
Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data
(Business Wire) -12.76%
Nov-05-24 04:01PM
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Sep-11-24 11:25PM
Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock
(Business Wire) +5.60%
Sep-10-24 04:01PM
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
(Business Wire) +32.14%
07:00AM
Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease
(Business Wire)
Sep-09-24 04:01PM
Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024
(Business Wire)
Sep-05-24 04:01PM
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire) -9.23%
Aug-08-24 08:15AM
Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results
(Business Wire)
Aug-07-24 04:01PM
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Jul-28-24 09:09AM
Goldman Sachs Predicts up to 165% Surge for These 2 Strong Buy Stocks
(TipRanks)
Jul-25-24 08:00AM
Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
(Business Wire)
Jul-08-24 10:38AM
3 Small-Cap Stocks With Explosive 2X Growth Potential
(InvestorPlace)
Jul-03-24 08:00AM
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Jun-27-24 09:48AM
Are Analysts Bullish on Viridian Therapeutics, Inc. (VRDN) Right Now?
(Insider Monkey)
Jun-26-24 04:36PM
Top 10 Small-Cap Stocks with Highest Upside Potential
(Insider Monkey)
Jun-12-24 09:11AM
Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug
(Zacks) -5.94%
Jun-11-24 06:00AM
Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease
(Business Wire) +10.15%
Jun-06-24 04:01PM
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
May-31-24 08:00AM
Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences
(Business Wire)
May-10-24 08:00AM
Viridian Therapeutics to Participate in Upcoming May Investor Conferences
(Business Wire)
May-09-24 03:02AM
Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
(GuruFocus.com) -6.64%
May-08-24 11:54AM
VRDN Stock Earnings: Viridian Therapeutics Beats EPS, Beats Revenue for Q1 2024
(InvestorPlace)
08:36AM
Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings: Narrowing Losses Amidst Clinical Advancements
(GuruFocus.com)
08:25AM
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates
(Zacks)
07:00AM
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results
(Business Wire)
May-03-24 08:00AM
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire) +5.62%
Apr-29-24 08:00AM
Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024
(Business Wire) +5.59%
Apr-04-24 04:01PM
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Mar-06-24 04:01PM
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Mar-05-24 08:00AM
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
(Business Wire)
Feb-28-24 09:55AM
How Much Upside is Left in Viridian Therapeutics, Inc. (VRDN)? Wall Street Analysts Think 97.81%
(Zacks)
Feb-27-24 04:01PM
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
(Business Wire)
Feb-16-24 08:00AM
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
(Business Wire)
Feb-06-24 04:01PM
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
Jan-17-24 10:00PM
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
(Business Wire) -9.73%
04:01PM
Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock
(Business Wire)
Jan-08-24 08:00AM
Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference
(Business Wire) +7.78%
Jan-04-24 08:00AM
Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference
(Business Wire)
Dec-18-23 07:00AM
Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease
(Business Wire) +9.52%
Nov-21-23 08:00AM
Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference
(Business Wire)
Nov-13-23 05:00PM
Viridian Therapeutics Inc (VRDN) Reports Q3 2023 Financial Results and Corporate Progress
(GuruFocus.com) +8.79%
04:01PM
Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
(Business Wire)
Nov-08-23 08:00AM
Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference
(Business Wire)
Nov-03-23 08:00AM
Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology
(Business Wire) +7.88%
Oct-30-23 08:30AM
Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing
(Business Wire) +5.17%
Oct-26-23 08:00AM
Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease
(Business Wire) +8.57%
Sep-25-23 08:00AM
Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors
(Business Wire)
Sep-07-23 08:00AM
Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September
(Business Wire)
Aug-08-23 04:01PM
Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
(Business Wire) +5.69%
Aug-04-23 04:01PM
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
(Business Wire)
Jul-10-23 04:01PM
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
(Business Wire) +5.06% -16.39%
Jul-06-23 04:05PM
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
(Business Wire)
Jun-13-23 08:00AM
Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Endocrine Society
(Business Wire)
Jun-05-23 04:05PM
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(Business Wire)
May-09-23 04:01PM
Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
(GlobeNewswire)
May-08-23 08:00AM
Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections
(GlobeNewswire)
May-04-23 04:05PM
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
May-02-23 08:00AM
Viridian Therapeutics to Webcast First Quarter 2023 Financial Results and Corporate Update on May 9, 2023
(GlobeNewswire)
Apr-20-23 01:41PM
UPDATE Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology
(GlobeNewswire)
08:00AM
Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology
(GlobeNewswire)
Apr-16-23 09:50AM
TipRanks Perfect 10 List: 2 Top-Rated Stocks Potentially Undervalued by ~90%
(TipRanks)
Apr-13-23 06:52AM
Daily Vickers Top Buyers & Sellers for 04/13/2023
(Argus Research)
Apr-12-23 08:00AM
Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer
(GlobeNewswire)
Apr-04-23 04:05PM
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Mar-08-23 07:00AM
Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
(GlobeNewswire) -10.48%
Mar-07-23 08:00AM
Viridian Therapeutics Announces Presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society
(GlobeNewswire)
Mar-03-23 04:05PM
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Mar-01-23 08:00AM
Viridian Therapeutics to Webcast Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023
(GlobeNewswire)
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fairmount Funds Management LLCDirectorJun 10 '25Option Exercise12.3112,500153,8753,459,913Jun 11 05:00 PM
Fairmount Funds Management LLCDirectorJun 09 '25Option Exercise7.801,60012,4803,447,413Jun 11 05:00 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Open in Screener

ZBIO

Zenas Biopharma Inc

Last Close
Oct 07  •  03:17PM ET
19.80
Dollar change
-3.23
Percentage change
-14.03 %
Healthcare • Biotechnology • USA • NASD
ZBIO Zenas Biopharma Inc daily Stock Chart
Held by: VTI IWM IWN DWAS SCHA VXF VTWO FESM IWC SBIO
IndexRUT P/E- EPS (ttm)-4.23 Insider Own75.52% Shs Outstand42.09M Perf Week-10.81%
Market Cap833.78M Forward P/E- EPS next Y-4.33 Insider Trans0.00% Shs Float10.31M Perf Month-7.97%
Enterprise Value561.51M PEG- EPS next Q-0.67 Inst Own35.90% Short Float53.84% Perf Quarter88.75%
Income-177.01M P/S55.59 EPS this Y71.19% Inst Trans5.62% Short Ratio26.77 Perf Half Y155.48%
Sales15.00M P/B3.48 EPS next Y-26.53% ROA-71.80% Short Interest5.55M Perf YTD141.76%
Book/sh5.69 P/C3.05 EPS next 5Y32.56% ROE-88.40% 52W High26.25 -24.57% Perf Year5.83%
Cash/sh6.49 P/FCF- EPS past 3/5Y-9.85% - ROIC-73.80% 52W Low5.83 239.62% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin99.31% Volatility10.16% 9.33% Perf 5Y-
Dividend TTM- EV/Sales37.43 EPS Y/Y TTM- Oper. Margin-1260.67% ATR (14)2.04 Perf 10Y-
Dividend Ex-Date- Quick Ratio5.23 Sales Y/Y TTM- Profit Margin-1180.04% RSI (14)50.14 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio5.23 EPS Q/Q-25.86% SMA20-2.26% Beta-1.67 Target Price32.43
Payout- Debt/Eq0.00 Sales Q/Q- SMA508.94% Rel Volume1.21 Prev Close23.03
Employees130 LT Debt/Eq0.00 EarningsAug 12 BMO SMA20071.57% Avg Volume207.35K Price19.80
IPOSep 13, 2024 Option/ShortYes / Yes EPS/Sales Surpr.-20.42% -100.00% Trades Volume224,925 Change-14.03%
Date Action Analyst Rating Change Price Target Change
Mar-20-25Initiated Wedbush Outperform $35
Feb-04-25Initiated Wolfe Research Outperform $19
Dec-16-24Initiated H.C. Wainwright Buy $30
Nov-05-24Initiated Rodman & Renshaw Buy $34
Oct-08-24Initiated Morgan Stanley Overweight $40
Oct-08-24Initiated Jefferies Buy $35
Oct-08-24Initiated Guggenheim Buy $45
Oct-08-24Initiated Citigroup Buy $27
Sep-02-25 07:05AM
Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million
(GlobeNewswire) +9.50%
Aug-26-25 07:05AM
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
(GlobeNewswire)
Aug-12-25 07:05AM
Zenas BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
(GlobeNewswire) +6.68%
Jun-20-25 04:15PM
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
Jun-13-25 05:45AM
Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO
(PR Newswire) -8.75%
04:00AM Loading…
Jun-02-25 04:00AM
ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO
(PR Newswire) +5.67%
May-29-25 07:05AM
Zenas BioPharma to Present at the Jefferies Global Healthcare Conference
(GlobeNewswire) +8.34%
May-28-25 09:31AM
ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO
(PR Newswire) -12.59%
May-16-25 05:45AM
Investors in Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO
(PR Newswire) +7.49%
May-15-25 07:05AM
Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates
(GlobeNewswire) +12.21%
May-06-25 05:45AM
Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO
(PR Newswire) -19.71%
May-02-25 05:45AM
Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO
(PR Newswire)
Apr-29-25 05:45AM
Zenas BioPharma, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO
(PR Newswire) +12.56%
Apr-22-25 10:37AM
Cohen Milstein Calls on Zenas BioPharma (ZBIO) Investors to Act Following Significant Post-IPO Losses
(GlobeNewswire)
Apr-21-25 12:33PM
Zenas Biopharma Investors Urged to Contact Cohen Milstein After Post-IPO Losses
(GlobeNewswire) +9.30%
04:20PM Loading…
Apr-17-25 04:20PM
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +7.08%
Apr-07-25 03:08PM
Zenas: Differentiated B-Cell Targeting Drug With Q3 Of 2025 Catalyst
(Seeking Alpha)
07:05AM
Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer
(GlobeNewswire)
Mar-20-25 02:54PM
Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress
(Benzinga)
11:41AM
Zenas Bio rises as Wedbush launches with Outperform on lead asset
(SeekingAlpha)
Mar-17-25 07:05AM
Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer
(GlobeNewswire)
Feb-05-25 07:05AM
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases
(GlobeNewswire)
Jan-28-25 08:00AM
Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference
(GlobeNewswire)
Dec-17-24 06:25AM
Zenas BioPharma initiated with a Buy at H.C. Wainwright
(TipRanks) +8.10%
Dec-12-24 07:35AM
Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley
(TipRanks)
Nov-12-24 07:10AM
Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
(GlobeNewswire)
07:05AM
Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)
(GlobeNewswire)
Nov-07-24 07:05AM
Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences
(GlobeNewswire)
Oct-14-24 06:45AM
Opening Day: Another trio of biotech IPOs make Friday debut
(TipRanks) +7.63%
Sep-19-24 04:15PM
Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering
(GlobeNewswire) +8.45%
04:09PM Loading…
Sep-13-24 04:09PM
Biotech IPO Shares Climb in Debuts After Deals Upsized
(Bloomberg)
12:19AM
Bicara Leads Trio of US Biotech IPOs Raising $703 Million
(Bloomberg)
Sep-12-24 10:37PM
Zenas BioPharma Announces Pricing of Upsized Initial Public Offering
(GlobeNewswire)
Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MOULDER LEON O JRChief Executive OfficerFeb 18 '25Buy6.6725,000166,750266,155Feb 19 04:01 PM
Xiao TingDirectorFeb 07 '25Buy7.7610,00077,60047,000Feb 11 04:20 PM
MOULDER LEON O JRChief Executive OfficerDec 04 '24Buy9.9845,000449,100241,155Dec 04 09:03 PM
MOULDER LEON O JRChief Executive OfficerDec 03 '24Buy10.7625,000269,000196,155Dec 04 09:03 PM
MOULDER LEON O JRChief Executive OfficerNov 18 '24Buy15.007,500112,500168,655Nov 20 05:20 PM
MOULDER LEON O JRChief Executive OfficerNov 19 '24Buy14.572,50036,425171,155Nov 20 05:20 PM
open in screener | open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.